Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email publishing@financialexpress.net in the first instance.

 Information  X 
Enter a valid email address

BTG PLC (BTG)

  Print      Mail a friend       Annual reports

Wednesday 25 January, 2012

BTG PLC

Interim Management Statement

RNS Number : 1335W
BTG PLC
25 January 2012
 



BTG plc: Interim Management Statement

 

London, UK, 25 January 2012: BTG plc (LSE: BGC), the specialist healthcare company, today publishes its interim management statement for the period from 1 October 2011 to 24 January 2012.

 

Trading has been in line with the Board's expectations and revenues for the full year are expected to be in the range £160m to £165m, as previously announced. This guidance excludes any royalty revenues that may be received in the second half relating to BeneFIX® (factor IX) product that was in the supply chain at the time of final patent expiry in March 2011.

 

The Biologics License Application for Voraxaze® (glucarpidase) that was submitted to the US Food and Drug Administration in September 2011 was granted priority review and was approved on 17 January 2012. Voraxaze® is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per litre) in patients with delayed methotrexate clearance due to impaired renal function. It will be marketed directly in the US by BTG through our existing acute care sales force; we anticipate peak US sales of around $15m per annum. BTG licensed the Japanese rights to glucarpidase to Ohara Pharmaceutical Co., Ltd. in December 2011.

 

BTG's new team of Medical Science Liaisons and Account Managers commenced direct sales of and medical support for the LC Bead™ in the US this month following expiry of the distribution contract with AngioDynamics, Inc. on 31 December 2011. The team has made good initial progress, with all key accounts updated with new order codes and first orders received. The revenue impact of selling the LC Bead™ in the US ourselves is expected to be evident from the financial year beginning in April 2012.

 

Analysis of data from the Phase III trials of Varisolve® (PEM) is continuing with the results of all three studies expected within the first half of 2012.

 

Louise Makin, BTG's CEO, commented: "We have continued to make good progress commercially and in our pipeline since reporting in November a strong set of results for the first half of the year. Our second US sales force is now selling the LC Bead™ and has started well. We were pleased to receive US approval for Voraxaze®, the first regulatory application we have made in the US, which we will market through our existing acute care sales force. We look forward to a busy 2012, with data from the three Phase III trials of Varisolve®, from our partner AstraZeneca's Phase IIb study of AZD9773 (CytoFab™) in severe sepsis and the submission of US and EU regulatory applications by Sanofi for Lemtrada™ (alemtuzumab) in relapsing-remitting multiple sclerosis."

 

 

For further information please contact:

 

BTG

FTI Consulting


Andy Burrows, Director of Investor Relations

Ben Atwell


+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605


+44 (0)20 7831 3113




Rolf Soderstrom, Chief Financial Officer



+44 (0)20 7575 0000  



 

About BTG

BTG is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The Group is seeking to acquire new products to develop and market to specialist physicians, and is building a sustainable business financed by revenues from sales of its own marketed products and from royalties and milestone payments on partnered products. For further information about BTG please visit our website at www.btgplc.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSQELBLLFFEBBF